Cycle on Jul 10, 2026

I will start by listing the active threads for this topic to see if there are any specific user-prioritized research questions or watches we need to address or follow up on.

I will now search for recent healthcare and science developments, focusing on our active watches. In particular, we have a few watches with deadlines in late July 2026 or with highly active timelines: 1. Capricor's deramiocel FDA Advisory Committee meeting scheduled for July 29, 2026. 2. Replimune's RP1 FDA Advisory Committee meeting scheduled for late July 2026 (PDUFA Aug 2, 2026). 3. Amgen's Tavneos FDA hearing submission extended deadline (July 29, 2026). 4. Any updates on H5N1 in Australia or elsewhere. 5. Other major clinical trial readouts or regulatory updates. Let's do some searches for "Capricor deramiocel advisory committee", "Replimune RP1 advisory committee", and "Amgen Tavneos FDA". I'll also do a general search for recent pharma and science news.

The Capricor advisory committee is indeed set for July 29, 2026. Let's fetch the biospace article to get more details on why they say "Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy". This will help us understand if there are new developments or context on this watch!

I will search for the specific date of Replimune's RP1 FDA advisory committee meeting to verify the details.

Let's look for the exact date of Replimune's RP1 ODAC/advisory committee meeting. Let's do a search on "Replimune RP1 advisory committee date".

Excellent. Both Capricor's BLA for deramiocel and Replimune's BLA for RP1 have been accepted for review, each receiving an FDA Advisory Committee meeting. Now let's check on Amgen's Tavneos (avacopan). The watch description says: "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-adjudication of the ADVOCATE trial data and the formal request for an FDA hearing." The extended deadline is July 29, 2026. Let's search for "Amgen Tavneos FDA hearing Duke Clinical Research Institute July 2026".

Let's check if there are any new updates on the Amgen Tavneos front. It says the submission is due by July 29, 2026, which is still a few weeks away. Let's fetch the `appliedclinicaltrialsonline.com` article from July 2026 to see if anything happened in the last week.

This provides excellent details for updating the Tavneos finding if needed, but we already have a prior finding for it: `amgen-tavneos-eu-revocation-us-fda-extension`. The current status is that the deadline for Amgen's hearing submission remains July 29, 2026. Let's do a search on other watches, like H5N1 in Australia or elsewhere, and check if there are any updates. Let's search "Australia H5N1 wild birds poultry July 2026".

This is a major and highly consequential development. Let's fetch the Reuters article or the Sydney Morning Herald article (`smh.com.au`) to get the exact details of the first H5N1 case in a local/native Australian seabird and the suspected case in a seal. This is directly relevant to our ongoing watch `019f2f50-7f4d-7361-8f05-cdf170c2d727` ("Australia H5N1 transmission to poultry or local wildlife"). Let's fetch `smh.com.au` first.

This is a huge development! The H5N1 strain has jumped from subantarctic migratory seabirds to a local species (**greater crested tern**) in South Australia, which is a major escalation. This means we have triggered our ongoing watch: `019f2f50-7f4d-7361-8f05-cdf170c2d727` ("Australia H5N1 transmission to poultry or local wildlife"). Let's record the event on this thread! First, let's see if there are any other details or other watches we can check. Let's search for "Vera Therapeutics Phase 3 ORIGIN 3" or other active watches. Let's do a search.

This is another massive regulatory and clinical milestone! Vera Therapeutics' **TRUTAKNA (atacicept)** has received FDA accelerated approval for adult patients with primary IgA nephropathy (IgAN). The approval happened on or around July 7-8, 2026. This is a brand new approval, and it directly relates to our watch `019f3ec3-9518-7baa-a4e4-19e437e0557f` ("Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN"). The accelerated approval is based on 36-week proteinuria reduction, and continued approval is dependent on verifying kidney-function benefit (eGFR data expected in Q3 2026). Let's fetch the Fierce Pharma article (`https://www.fiercepharma.com/pharma/fda-approves-vera-therapeutics-atacicept-setting-igan-market-battle-novartis-otsuka`) to get all the details and quotes. This is critical for writing a high-quality note on Trutakna's approval and the IgAN landscape.

Wow, this contains several incredible, high-salience updates: 1. **Vera Therapeutics' Trutakna (atacicept)** has received FDA accelerated approval (on or around July 7-8, 2026) for adult patients with primary IgA nephropathy (IgAN). The approval is based on a 42% reduction in UPCR at 36 weeks in the Phase 3 ORIGIN 3 trial. 2. **Hengrui and Elevar's camrelizumab-rivoceranib combo** was rejected by the FDA for a **third time** in first-line liver cancer on July 10, 2026, due to manufacturing deficiencies at the plant producing rivoceranib (apatinib). 3. **Robert F. Kennedy Jr.’s HHS** has formally **ended the emergency use authorizations (EUAs)** that remain for COVID-19 drugs, biological products, and medical devices. The termination will take effect in a year (July 2027), affecting products like Invivyd's Pemgarda. 4. **Pfizer and Astellas' Padcev + Merck's Keytruda combo** has won FDA approval on July 10, 2026, for perioperative muscle-invasive bladder cancer (MIBC), regardless of cisplatin eligibility, more than a month ahead of its August 17 PDUFA date. 5. **Australia's H5N1 outbreak** has escalated as the virus has jumped to a local/native bird species, the **greater crested tern**, in South Australia. This is the first local species to test positive, though a NSW fur seal tested negative. These are incredibly rich, timely, and consequential updates that perfectly fit the "Track consequential science and health" brief. Let's address the threads/watches: - **Australia H5N1 transmission to poultry or local wildlife** (`019f2f50-7f4d-7361-8f05-cdf170c2d727`): We have confirmed transmission of H5N1 to local wildlife (the greater crested tern). It is a native Australian species. Let's record this event! - **Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN** (`019f3ec3-9518-7baa-a4e4-19e437e0557f`): This watch is for the confirmatory eGFR results expected in Q3 2026 to support the accelerated approval. The accelerated approval was just granted on July 7-8, 2026. This watch is not yet fired because the eGFR results are still expected later in Q3 2026, but we can write a note on the accelerated approval of Trutakna! - **FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy** (`019f061f-f34a-7079-a276-d216329928b2`): The meeting date has been confirmed for July 29, 2026. This is a dated catalyst watch, not yet fired, but we can update our findings. - **FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma** (`019f0620-0add-7ac7-9db1-1ce428418522` or `019f0620-007b-7dab-87b4-0363a2496ea1`): The FDA set an advisory committee meeting in late July and a PDUFA date of August 2, 2026. Let's write notes for these highly consequential developments. First, let's record the event for the Australia H5N1 watch. The watch is `ongoing`. Let's trigger it.

Now let's write or update the notes. We have: 1. **Australia H5N1 Escalation**: Let's create a new note on the H5N1 outbreak in Australia, specifically tracking the jump to local native wildlife. Let's name the slug `australia-h5n1-wildlife-transmission`. 2. **Vera's Trutakna Approval**: Let's write a note on the FDA accelerated approval of Trutakna (atacicept) and the competitive IgAN landscape. Let's name the slug `vera-trutakna-fda-accelerated-approval-igan`. 3. **FDA Regulatory Pivot**: The prior finding `fda-regulatory-pivot-advisory-committees-capricor-replimune` covers the post-Makary FDA pivot, including Capricor and Replimune. We have updates on both of these (FDA setting the advisory committee for Capricor on July 29, 2026, and Replimune's RP1 resubmission accepted with an AdComm in late July and a PDUFA of Aug 2, 2026). Let's update `fda-regulatory-pivot-advisory-committees-capricor-replimune` with these updates! 4. **Hengrui and Elevar's camrelizumab-rivoceranib 3rd CRL**: Let's create a new note or see if we have a previous slug. We don't have a previous slug for Hengrui/Elevar in the relevant prior findings. Let's create a new note with slug `hengrui-elevar-camrelizumab-rivoceranib-fda-crl`. 5. **HHS Ends COVID-19 EUAs**: This is a major policy move under Robert F. Kennedy Jr. Let's create a new note with slug `hhs-ends-covid-19-emergency-use-authorizations`. Let's write/update these notes one by one. Let's write the note for **Australia H5N1 Escalation**: `australia-h5n1-wildlife-transmission`.

Now, let's write the note for **Vera's Trutakna Approval**: `vera-trutakna-fda-accelerated-approval-igan`. Let's create this note.

Now let's update the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune` to reflect the new developments for both Capricor and Replimune. Let's first read the existing note to see its current structure and content. I will fetch the note's content using `read_notes` or search for it. Let's list the notes first.

Let's fetch the contents of `fda-regulatory-pivot-advisory-committees-capricor-replimune` so we can update it properly. I'll read the note first. Since I don't have a direct `read_note` tool, I will use `write_note` to overwrite/update it, but wait, let's see if there is any other way to view it. Ah, the `read_notes` output doesn't give the full body, but the preview is: "The U.S. Food and Drug Administration (FDA), under acting Commissioner Kyle Diamantas, is undergoing a profound operational and regulatory shift. Following the exit of former Commissioner Marty..." Wait, let's search for "The Post-Makary FDA Pivot" or look at the preview. I can write a fresh, comprehensive update to `fda-regulatory-pivot-advisory-committees-capricor-replimune` that incorporates both the historical context of the post-Makary shifts and the brand new July 2026 confirmations of Advisory Committee dates for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (late July 2026). Let's write the updated note.

Now let's write the note for **Hengrui and Elevar's camrelizumab-rivoceranib 3rd CRL**: `hengrui-elevar-camrelizumab-rivoceranib-fda-crl`. Let's create this note.

Now let's write the note for **HHS Ends COVID-19 EUAs**: `hhs-ends-covid-19-emergency-use-authorizations`. Let's create this note.

We have written and updated all our notes. Let's finish the cycle now. I will call `finish_cycle`.

I have completed the research cycle for this topic. Here is a summary of the key findings and actions taken: ### 1. **Escalation of H5N1 Bird Flu in Australia** * **Finding:** The H5N1 avian influenza strain has officially jumped to a local, native bird species in mainland Australia. On July 10, 2026, the South Australian government confirmed that a **greater crested tern** tested positive on the Limestone Coast. This represents a major escalation from previous detections, which were confined to subantarctic migratory species. * **Actions:** Updated the ongoing watch thread **"Australia H5N1 transmission to poultry or local wildlife"** with a recorded event (`019f2f50-7f4d-7361-8f05-cdf170c2d727`), and created a new finding note: `australia-h5n1-wildlife-transmission`. ### 2. **FDA Accelerated Approval of Vera's Trutakna (Atacicept)** * **Finding:** On July 7, 2026, the FDA granted accelerated approval to Vera Therapeutics' **Trutakna (atacicept-vymj)** for primary IgA nephropathy (IgAN). Trutakna is the first approved dual inhibitor of BAFF and APRIL, showing a 42% reduction in proteinuria at 36 weeks. The company has aligned with the FDA to pull forward its confirmatory eGFR kidney function analysis to Q3 2026. * **Actions:** Created a new finding note: `vera-trutakna-fda-accelerated-approval-igan`. ### 3. **The Post-Makary FDA Pivot** * **Finding:** The FDA's return to regulatory normalcy and independent panel reviews under acting Commissioner Kyle Diamantas is picking up speed. Two highly anticipated resubmissions have had their independent Advisory Committee dates confirmed: * **Capricor's deramiocel** (DMD cardiomyopathy cell therapy): Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting scheduled for **July 29, 2026** (PDUFA: August 22, 2026). * **Replimune's RP1** (advanced melanoma oncolytic immunotherapy): FDA accepted the resubmission as a Class 1 response with an Advisory Committee meeting planned for **late July 2026** (PDUFA: August 2, 2026). * **Actions:** Updated the existing note `fda-regulatory-pivot-advisory-committees-capricor-replimune` with these confirmed summer 2026 dates. ### 4. **Hengrui and Elevar's Third FDA Rejection** * **Finding:** On July 10, 2026, the FDA issued a third Complete Response Letter (CRL) rejecting the camrelizumab-rivoceranib combination for first-line liver cancer. While previous rejections centered on camrelizumab, this third rejection was triggered by manufacturing compliance issues at the facility producing rivoceranib (apatinib). * **Actions:** Created a new finding note: `hengrui-elevar-camrelizumab-rivoceranib-fda-crl`. ### 5. **HHS Terminates Remaining COVID-19 EUAs** * **Finding:** HHS Secretary Robert F. Kennedy, Jr. announced the formal termination of remaining COVID-19 Emergency Use Authorizations (EUAs), effective in one year (July 2027). This forces remaining authorized products—such as Invivyd's prophylactic antibody Pemgarda—to seek traditional BLA/NDA approvals. * **Actions:** Created a new finding note: `hhs-ends-covid-19-emergency-use-authorizations`.